medigraphic.com
ISSN 1527-3172 (Electronic)

2021, Number 2

<< Back Next >>

MEDICC Review 2021; 23 (2)

Implications of Low-grade Inflammation in SARS-CoV-2 Immunopathology

Suárez-Reyes A, Villegas-Valverde CA

Language: English
References: 124
Page: 42-54
PDF size: 523.12 Kb.


ABSTRACT

INTRODUCTION Advanced age and chronic disease comorbidities are indicators of poor prognosis in COVID-19 clinical progression. Fatal outcomes in patients with these characteristics are due to a dysfunctional immune response. Understanding COVID-19’s immunopathogenesis helps in designing strategies to prevent and mitigate complications during treatment.
OBJECTIVE Describe the main immunopathogenic alterations of COVID-19 in patients of advanced age or with chronic non-communicable diseases.
DATA ACQUISITION We carried out a bibliographic search of primary references in PubMed, Elsevier, Science Direct and SciELO. A total of 270 articles met our initial search criteria. Duplicate articles or those unrelated to at least one chronic comorbidity, senescence or infl ammation and those that studied only patient clinical characteristics, laboratory tests or treatments were excluded. Finally, our selection included 124 articles for analysis: 10 meta-analyses, 24 original research articles, 67 review articles, 9 editorials, 9 comments, 3 books and 2 websites.
DEVELOPMENT Hypertension and diabetes mellitus are the most common comorbidities in COVID-19 patients. Risk of developing severe manifestations of the disease, including death, is increased in senescent and obese patients and those with cardiovascular disease, cancer or chronic obstructive pulmonary disease. Low-grade chronic infl ammation is characteristic of all these conditions, refl ected in a proinfl ammatory state, endothelial dysfunction, and changes to innate immunity; mainly of the monocyte-macrophage system with changes in polarization, infl ammation, cytotoxicity and altered antigenic presentation. In the case of SARS-CoV-2 infection, mechanisms involved in acute infl ammation overlap with the patient’s pro-infl ammatory state, causing immune system dysfunction. SARS-CoV-2 infection amplifi es already-existing alterations, causing failures in the immune system’s control mechanisms. The resulting cytokine storm causes an uncontrolled systemic infl ammatory response marked by high serum levels of infl ammatory biomarkers and a pro-infl ammatory cytokine profi le with decompensation of underlying diseases. In asthma, chronic eosinophilic infl ammation protects against infection by producing a reduced interferon-mediated response and a reduced number of ACE2 receptors.
CONCLUSIONS Low-grade chronic infl ammation present in advanced age and chronic diseases—but not in bronchial asthma—produces a pro-inflammatory state that triggers a dysregulated immune response, favoring development of severe forms of COVID-19 and increasing lethality.


REFERENCES

  1. Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X, et al.COVID-19: epidemiology, evolution, and crossdisciplinaryperspectives. Trends Mol Med. 2020May 1;26(5):483–95.

  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, etal. Clinical features of patients infected with 2019novel coronavirus in Wuhan, China. Lancet. 2020Feb 15;395(10223):497–506.

  3. Han Q, Lin Q, Jin S, You L. Coronavirus 2019-nCoV: a brief perspective from the front line. JInfect. 2020 Apr 1;80(4):373–7.

  4. Fuk-Woo CJ, Kok K, Zhu Z, Chu H, Kai-WangTK, Yuan S, et al. Genomic characterization ofthe 2019 novel human pathogenic coronavirusisolated from a patient with atypical pneumoniaafter visiting Wuhan. Emerg Microbes Infect.2020 Jan 28;9(1):221–36.

  5. Shereen MA, Khan S, Kazmi A, Bashir N, SiddiqueR. COVID-19 infection: origin, transmission,and characteristics of human coronaviruses.J Adv Res. 2020 Mar 16;24:91–8.

  6. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2outbreak: what we know. Int J Infect Dis. 2020May;94:44–8.

  7. Hoque MN, Chaudhury A, Akanda MdAM, HossainMA, Islam Md Tofazzal. Genomic diversityand evolution, diagnosis, prevention, and therapeuticsof the pandemic COVID-19 disease. PeerJ. 2020 Sep 1;8:e9689. DOI: 10.7717/peerj.9689

  8. Ovsyannikova IG, Haralambieva IH, Crooke SN,Poland GA, Kennedy RB. The role of host geneticsin the immune response to SARSCoV-2 andCOVID-19 susceptibility and severity. ImmunolRev. 2020 Jul;296(1):205–19.

  9. Gill SE, Dos Santos CC, O’Gorman DB, CarterDE, Patterson EK, Slessarev M, et al. Transcriptionalprofi ling of leukocytes in critically illCOVID19 patients: implications for interferonresponse and coagulation. Intensive Care MedExp. 2020 Dec 11;8:75. DOI: 10.1186/s40635-020-00361-9

  10. McCoy K, Peterson A, Tian Y, Sang Y. Immunogeneticassociation underlying severeCOVID-19. Vaccines (Basel). 2020 Nov20;8(4):700.

  11. Di Maria E, Latini A, Borgiani P, Novelli G.Genetic variants of the human host infl uencingthe coronavirus-associated phenotypes (SARS,MERS and COVID-19): rapid systematic reviewand fi eld synopsis. Hum Genomics. 2020 Sep11;14(1):30.

  12. Kenney AD, Dowdle JA, Bozzacov L, McMichaelTM, Gelais CS, Panfi l AR, et al. Human geneticdeterminants of viral diseases. Annu Rev Genet.2017 Nov 27;51:241–63.

  13. Wang X, Fang X, Cai Z, Wu X, Gao X, MinJ, et al. Comorbid chronic diseases and acuteorgan injuries are strongly correlated with diseaseseverity and mortality among COVID-19patients: a systemic review and meta-analysis.Research (Wash DC). 2020;2402961. DOI:10.34133/2020/2402961

  14. Liu H, Chen Sh, Liu M, Nie H, Lu H. Comorbidchronic diseases are strongly correlated withdisease severity among COVID-19 patients: asystematic review and meta-analysis. Aging Dis.2020 May 9;11(3):668–78.

  15. Fu L, Wang B, Yuan T, Chen X, Ao Y, FitzpatricT, et al. Clinical characteristics of coronavirusdisease 2019 (COVID-19) in China: a systematicreview and meta-analysis. J Infec. 2020Jun;80(6):656–65.

  16. Rodríguez-Morales AJ, Cardona-Ospina JA,Gutiérrez-Ocampo E, Villamizar-Peña R, Holguín-Rivera Y, Escalera-Antezana JP, et al.Clinical, laboratory and imaging features ofCOVID-19: a systematic review and metaanalysis.Travel Med Infect Dis. 2020 Mar–Apr;34:101623. DOI: 10.1016/j.tmaid.2020.101623

  17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, etal. Clinical characteristics of 138 hospitalizedpatients with 2019 Novel Coronavirus-infectedpneumonia in Wuhan, China. JAMA. 2020 Mar17;323(11):1061–9.

  18. Jain V, Yuan JM. Predictive symptoms andcomorbidities for severe COVID-19 and intensivecare unit admission: a systematic reviewand meta-analysis. Int J Public Health. 2020Jun;65(5):533–46.

  19. Kang SJ, Jung SI. Age-related morbidity andmortality among patients with COVID-19. InfectChemother. 2020 Jun;52(2):154–64.

  20. Shahid Z, Kalayanamitra R, McClafferty B,Kepko D, Ramgobin D, Patel R, et al. COVID-19and older adults: what we know. J Am GeriatrSoc. 2020 May;68(5):926–9.

  21. Tay MZ, Poh CM, Rénia L, MacAry PA, NgLFP. The trinity of COVID-19: immunity, infl ammationand intervention. Nat Rev Immunol. 2020Jun;20(6):363–74.

  22. Comunicado de Prensa. Creciendo a un ritmomenor, se espera que la población mundialalcanzará 9.700 millones en 2050 y unmáximo de casi 11.000 millones alrededor de2100: Informe de la ONU [Internet]. New York:United Nations, Department of Public Information;2019 [cited 2020 Dec 24]. 4 p. Available at:https://population.un.org/wpp/Publications/Files/WPP2019_PressRelease_ES.pdf. Spanish.

  23. World Health Organization [Internet]. Geneva:World Health Organization; c2021. Newsroom.Fact sheets. Enfermedades no transmisibles;[updated 2018 Jun 1; cited 2020 Dec 24]. Availableat: https://www.who.int/es/news-room/fact-sheets/detail/noncommunicable-diseases.Spanish.

  24. National Health Statistics and Medical RecordsDivision (CU). Anuario Estadístico de Salud2019 [Internet]. Havana: Ministry of Public Health(CU); 2020 [cited 2020 Dec 24]. 206 p. Availableat: http://www.sld.cu/anuncio/2020/05/09/publicado-el-anuario-estadistico-de-salud-2019.Spanish.

  25. Horton R. Offl ine: COVID-19 is not a pandemic.Lancet. 2020 Sep 26;396(10255):874.

  26. Prete M, Favoino E, Catacchio G, Racanelli V,Perosa F. SARS-CoV-2 Infl ammatory Syndrome.Clinical features and rationale for immunologicaltreatment. Int J Mol Sci. 2020 May 10;21(9):3377.

  27. Abbas AK, Litchman AH, Pillai S. Inmunologíacelular y molecular. 8va. ed. Barcelona: ElsevierEspaña; 2015. Chapter 1, Propiedades y generalidadesde las respuestas inmunitarias; p. 1–12.Spanish.

  28. Fulop T, Larbi A, Dupuis G, Le Page A, FrostEH, Cohen AA, et al. Immunosenescenceand infl amm-aging as two sides of the samecoin: friends or foes? Front Immunol. 2018 Jan10;8:1960. DOI: 10.3389/fi mmu.2017.01960

  29. Vabret N, Britton GJ, Gruber C, Hegde S, KimJ, Kuksin M, et al. Immunology of COVID-19:current state of the science. Immunity. 2020 Jun16;52(6):910–41.

  30. Jonsdottir HR, Dijkman R. Coronaviruses and thehuman airway: a universal system for virus-hostinteraction studies. Virol J. 2016 Feb 6;13:24.DOI: 10.1186/s12985-016-0479-5

  31. Nikolich-Zugich J, Knox KS, Tafi ch Rios C, NattB, Bhattacharya D, Fain MJ. SARS-CoV-2 andCOVID-19 in older adults: what we may expectregarding pathogenesis, immune responses, andoutcomes. GeroScience. 2020 Apr;42(2):505–14.

  32. Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S,Nemati M. Contribution of monocytes and macrophagesto the local tissue infl ammation and cytokinestorm in COVID-19: Lessons from SARSand MERS, and potential therapeutic interventions.Life Sci. 2020 Sep 15;257:118102. DOI:10.1016/j.lfs.2020.118102

  33. Rohit G, Abdou Y, Singh A, Rana N, Puzanov I,Ernstoff MS. COVID-19 and cancer: a comprehensivereview. Curr Oncol Rep. 2020 May8;22(5):53. DOI: 10.1007/s11912-020-00934-7

  34. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y,et al. COVID-19 infection induces readily detectablemorphologic and infl ammation-related phenotypicchanges in peripheral blood monocytes.J Leukoc Biol. 2021 Jan;109(1):13–22.

  35. Pence BD. Severe COVID-19 and aging:are monocytes the key? GeroScience. 2020Aug;42(4):1051–61.

  36. Bektas A, Schurman SH, Franceschi C, FerrucciL. A public health perspective of aging: do hyperinflammatory syndromes such as COVID-19,SARS, ARDS, cytokine storm syndrome, andpost-ICU syndrome accelerate short- and longterminfl ammaging? Immun Ageing. 2020 Aug24;17:23 DOI: 10.1186/s12979-020-00196-8

  37. Figueira Gonçalves JM, Golpe R. Clinical challengesin chronic obstructive pulmonary diseasein patients who suffered SARS-CoV-2 infection.Med Clin (Barc). 2020 Aug 28;155(4):162–4.English, Spanish.

  38. Sardu C, Gambardella J, Morelli MB, Wang X,Marfella R, Santulli G. Hypertension, thrombosis,kidney failure, and diabetes: is COVID-19 anendothelial disease? A comprehensive evaluationof clinical and basic evidence. J Clin Med.2020 May;9(5):1417. DOI: 10.3390/jcm9051417

  39. Matsushita K, Marchandot B, Jesel L, OhlmannP, Morel O. Impact of COVID-19 on the cardiovascularsystem: a review. J Clin Med. 2020May;9(5):1407. DOI:10.3390/jcm9051407

  40. Mattioli AV, Puviani MB, Nasi M, Farinetti A.COVID-19 pandemic: the effects of quarantineon cardiovascular risk. Eur J Clin Nutr. 2020Jun;74(6):852–5.

  41. Mathew D, Giles JR, Baxter AE, Oldridge DA,Greenplate AR, Wu JE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypeswith therapeutic implications. Science.2020 Sep 4;369(6508):eabc8511. DOI: 10.1126/science.abc8511

  42. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, SavvatisK, Marelli-Berg FM, et al. COVID-19 andthe cardiovascular system: implications for riskassessment, diagnosis, and treatment options.Cardiovasc Res. 2020 Aug 1;116(10):1666–87.

  43. Addeo A, Friedlaender A. Cancer and COVID-19:unmasking their ties. Cancer Treat Rev. 2020Aug;88:102041. DOI: 10.1016/j.ctrv.2020.102041

  44. Krabbe KS, Pedersen M, Bruunsgaard H. Infl ammatorymediators in the elderly. Exp Gerontol.2004 May;39(5):687–99.

  45. Medzhitov R. Origin and physiologicalroles of infl ammation. Nature. 2008 Jul24;454(7203):428–35.

  46. Chung HY, Kim DH, Lee EK, Chung KW, ChungS, Lee B, et al. Redefi ning chronic infl ammationin aging and age-related diseases: proposal ofthe senoinfl ammation concept. Aging Dis. 2019Apr 1;10(2):367–82.

  47. Hawiger J, Zienkiewicz J. Decoding infl ammation,its causes, genomic responses, and emergingcountermeasures. Scand J Immunol. 2019Dec;90(6):e12812. DOI: 10.1111/sji.12812

  48. Ferrucci L, Fabbri E. Infl ammageing: chronic infl ammationin ageing, cardiovascular disease, and frailty.Nat Rev Cardiol. 2018 Sep;15(9):505–22.

  49. Rock KL, Latz E, Ontiveros F, Kono H. The sterileinfl ammatory response. Annu Rev Immunol.2010;28:321–42. DOI: 10.1146/annurev-immunol-030409-101311.

  50. Bektas A, Schurman SH, Sen R, FerrucciL. Human T cell immunosenescence andinfl ammation in aging. J Leukoc Biol. 2017Oct;102(4):977–88.

  51. Martínez–Aguilar NE, Vargas–Camaño ME,Hernández–Pliego RR, Chaia–Semerena GM,Pérez–Chavira MR. Inmunopatología de laenfermedad pulmonar obstructiva crónica. RevAlerg Mex. 2017;64(3):327–46. Spanish.

  52. Crouch EC, Hirche TO, Shao B, Boxio R, WartelleJ, Benabid R, et al. Myeloperoxidasedependentinactivation of surfactant proteinD in vitro and in vivo. J Biol Chem. 2010 May28;285(22):16757–70.

  53. Flaherty GT, Hession P, Liew CH, Wei LimBC, Leong TK, Lim V, et al. COVID-19 in adultpatients with preexisting chronic cardiac, respiratoryand metabolic disease: a critical literaturereview with clinical recommendations. TropDis Travel Med Vaccines. 2020 Aug 28;6:16DOI:10.1186/s40794-020-00118-y

  54. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G,et al. Risk factors for disease severity, unimprovement,and mortality in COVID-19 patientsin Wuhan, China. Clin Microbiol Infect. 2020Jun;26(6):767–72.

  55. Richardson S, Hirsch JS, Narasimhan M,Crawford JM, McGinn T, Davidson KW, et al.Presenting characteristics, comorbidities, andoutcomes among 5700 patients hospitalized withCOVID-19 in the New York City area. JAMA.2020 May 26;323(20):2052–9.

  56. Kowald A, Passos JF, Kirkwood TBL. On the evolutionof cellular senescence. Aging Cell. 2020Dec;19(12):e13270. DOI: 10.1111 / acel.13270

  57. Hamsanathan S, Alder JK, Sellares J, RojasM, Gurkar AU, Mora AL. Cellular senescence:the Trojan horse in chronic lung diseases. Am JRespir Cell Mol Biol. 2019 Jul;61(1):21–30.

  58. Nikolich-Zugich J. Ageing and life-long maintenanceof T-cell subsets in the face of latentpersistent infections. Nat Rev Immunol. 2008Jul;8(7):512–22.

  59. Suárez GM, Saavedra D. Manipulación de lainmunosenescencia. Rev Cubana HematolInmunol Hemoter [Internet]. 2018 Jan–Mar [cited2020 Dec 24];34(1):33–41. Available at: http://www.revhematologia.sld.cu/index.php/hih/article/view/584/767. Spanish.

  60. Thomas R, Wang W, Su DM. Contributionsof age-related thymicinvolution to immunosenescence and infl ammaging.Immun Ageing. 2020 Jan 20;17:2.DOI: 10.1186/s12979-020-0173-8

  61. Franceschi C, Monti D, Barbieri D, Salvioli S,Grassilli E, Capri M, et al. Successful immunosenescenceand the remodeling of immuneresponses with ageing. Nephrol Dial Transplant.1996;11 Suppl 9:18–25.

  62. Motta M, Ferlito L, Malaguarnera L, Vinci E, BoscoS, Maugeri D, et al. Alterations of the lymphocyticset-up in elderly patients with cancer. ArchGerontol Geriatr. 2003 Jan–Feb;36(1):7–14.

  63. García B, Lage A. Inmunosenescencia: implicacionespara la inmunoterapia de cáncer en los adultosmayores. Biotecnol Apl [Internet]. 2006 [cited2020 Dec 24];23:186–93. Available at: https://bibla t.unam.mx/es/revista/biotecnologia-aplicada/articulo/inmunosenescencia-implicaciones-para-la-inmunoterapia-de-cancer-en-los-adultos-mayores. Spanish.

  64. Fülöp T, Dupuis G, Witkowski JM, Larbi A. Therole of immunosenescence in the developmentof age-related diseases. Rev Inves Clin. 2016Mar–Apr;68(2):84–91.

  65. Agrawal A, Gupta S. Impact of aging on dendriticcell functions in humans. Ageing Res Rev. 2011Jul;10(3):336–45.

  66. Cunha LL, Perazzio SF, Azzi J, Cravedi P, RiellaLV. Remodeling of the immune response withaging: immunosenescence and its potentialimpact on COVID-19 immune response. FrontImmunol. 2020 Aug 7;11:1748. DOI: 10.3389/fi mmu.2020.01748

  67. Grubeck-Loebenstein B, Wick G. The aging of theimmune system. Adv Immunol. 2002;80:243–84.

  68. Pawelec G. Age and immunity: what is “immunosenescence”?Exp Gerontol. 2018 May;105:4–9.

  69. Yang JK, Lin SS, Ji XJ, Guo LM. Binding ofSARS coronavirus to its receptor damages isletsand causes acute diabetes. Acta Diabetol. 2010Sep;47(3):193–9.

  70. van Baarle D, Tsegaye A, Miedema F, Akbar A.Signifi cance of senescence for virus-specifi cmemory T cell responses: rapid ageing duringchronic stimulation of the immune system. ImmunolLett. 2005 Feb 15;97(1):19–29.

  71. Franceschi C, Monti D, Sansoni P, Cossarizza A.The immunology of exceptional individuals: thelesson of centenarians. Immunol Today. 1995Jan;16(1):12–6.

  72. Wang B, Li R, Lu Z, Huang Y. Does comorbidityincrease the risk of patients with COVID-19:evidence from meta-analysis. Aging (Albany NY).2020 Apr 8;12(7):6049–57.

  73. Ekiz T, Pazarl AC. Relationship between COVID-19 and obesity. Diabetes Metab Syndr. 2020Sep–Oct;14(5):761–3.

  74. Muscogiuri G, Pugliese G, Barrea L, SavastanoS, Colao A. Comentary: Obesity: The“Achilles heel” for COVID-19? Metabolism.2020 Jul 1;108:154251. DOI:10.1016/j.metabol.2020.154251

  75. Kumar A, Arora A, Sharma P, Anikhindi SA,Bansal N, Singla V, et al. Is diabetes mellitusassociated with mortality and severity ofCOVID-19? A meta-analysis. Diabetol MetabSyndr. 2020 Jul–Aug;14(4):535–45.

  76. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al.Prevalence and severity of corona virus disease2019 (COVID-19): a systematic review and metaanalysis.J Clin Virol. 2020 Jun;127:104371. DOI:10.1016/j.jcv.2020.104371

  77. ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Cámara R, etal. The risk and prognosis of COVID-19 infectionin cancer patients: a systematic review andmeta-analysis. Hematol Oncol Stem Cell Ther[Internet]. 2020 Jul 30 [cited 2020 Dec 24]. DOI:10.1016/j.hemonc.2020.07.005. Online ahead ofprint. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390725/

  78. Liang W, Guan W, Chen R, Wang W, Li J, Xu K,et al. Comment: Cancer patients in SARS-CoV-2infection: a nationwide analysis in China. LancetOncol. 2020 Mar;21(3):335–7.

  79. Barbé-Tuana F, Funchal G, Schmitz CRR, MaurmannRM, Bauer ME. The interplay betweenimmunosenescence and age-related diseases.Semin Immunopathol. 2020 Oct;42(5):545–57.

  80. Chait A, den Hartigh LJ. Adipose tissue distribution,inflammation and its metabolicconsequences, including diabetes and cardiovasculardisease. Front Cardiovasc Med. 2020Feb 25;7:22. DOI: 10.3389/fcvm.2020.00022

  81. Burhans MS, Hagman DK, Kuzma JN, SchmidtKA, Kratz M. Contribution of adipose tissueinfl ammation to the development of type 2 diabetesmellitus. Compr Physiol. 2018 Dec 13;9(1):1–58.

  82. Petrakis D, Margină D, Tsarouhas K, Tekos F,Stan M, Nikitovic D, et al. Obesity - a risk factorfor increased COVID-19 prevalence, severityand lethality. Mol Med Rep. 2020 Jul;22(1):9–19.

  83. Boutens L, Stienstra R. Adipose tissue macrophages:going off track during obesity. Diabetologia.2016 May;59(5):879–94.

  84. Geng S, Chen K, Yuan R, Peng L, Maitra U,Diao N, et al. The persistence of low-gradeinflammatory monocytes contributes to aggravatedaterosclerosis. Nat Commun. 2016 Nov8;7:13436. DOI: 10.1038/ncomms13436

  85. Laird E, Rhodes J, Kenny RA. Vitamin D andinfl ammation: potential implications for severityof COVID-19. Ir Med J. 2020 May 7;113(5):81.

  86. Li MY, Li L, Zhang Y, Wang XS. Expression ofthe SARS-CoV-2 cell receptor gene ACE2 in awide variety of human tissues. Infect Dis Poverty.2020 Apr 28;9(1):45. DOI: 10.1186/s40249-020-00662-x

  87. Al-Benna S. Association of high level geneexpression of ACE2 in adipose tissue with mortalityof COVID-19 infection in obese patients.Obes Med. 2020 Sep;19:100283. DOI: 10.1016/j.obmed.2020.100283

  88. Serra Valdés MA. Las enfermedades crónicasno transmisibles y la pandemia por COVID-19.Rev Finlay [Internet]. 2020 Jun [cited 2020 Dec25];10(2):78–88. Available at: http://www.revfinlay.sld.cu/index.php/finlay/article/view/846.Spanish.

  89. Williams B, Mancia G, Spiering W, RoseiEA, Azizi M, Burnier M, et al. 2018 ESC/ESHGuidelines for the management of arterial hypertension:The Task Force for the management ofarterial hypertension of the European Societyof Cardiology (ESC) and the European Societyof Hypertension (ESH). Eur Heart J. 2018 Sep1;39(33):3021–104.

  90. Wenzel U, Turner JE, Krebs C, Kurts C, HarrisonDG, Ehmke H. Immune mechanisms in arterialhypertension. J Am Soc Nephrol. 2016 Mar;27(3):677–86.

  91. Norlander AE, Madhur MS, Harrison DG. Theimmunology of hypertension. J Exp Med. 2018Jan 2;215(1):21–33.

  92. Siedlinski M, Jozefczuk E, Xu X, Teumer A, EvangelouE, Schnabel RB, et al. White blood cellsand blood pressure. A Mendelian randomizationstudy. Circulation. 2020 Apr 21;141(16):1307–17.

  93. Rodríguez-Iturbe B. The participation of immunityin the pathogenesis of arterial hypertension.Nefrologia. 2020 Jan–Feb;40(1):1–3. English,Spanish.

  94. Youn JC, Yu HT, Lim BJ, Koh MJ, Lee J, ChangDY, et al. Immunosenescent CD8+ T Cells andC-X-C chemokine receptor type 3 chemokinesare increased in human hypertension. Hypertension.2013 Jul;62(1):126–33.

  95. Virchow R. Cellular pathology. As based uponphysiological and pathological histology. LectureXVI--Atheromatous affection of arteries. 1858.Nutr Rev. 1989 Jan;47(1):23–5.

  96. Qu X, Tang Y, Hua S. Immunological approachestowards cancer and infl ammation: a crosstalk. Front Immunol. 2018 Mar 20;9:563. DOI:10.3389/fi mmu.2018.00563

  97. Schetter AJ, Heegaard NH, Harris CC. Infl ammationand cancer: interweaving microRNA, freeradical, cytokine and p53 pathways. Carcinogenesis.2010 Jan 1;31(1):37–49.

  98. Grivennikov SI, Greten FR, Karin M. Immunity,infl ammation, and cancer. Cell. 2010 Mar19;140(6):883–99.

  99. Munn L. Cancer and Infl ammation. Wiley InterdiscipRev Syst Biol Med. 2017 Mar;9(2). DOI:10.1002/wsbm.1370

  100. Aguilar-Cazares D, Chavez-Domínguez R, Carlos-Reyes A, López-Camarillo C, Hernández dela Cruz ON, López-González JS. Contributionof angiogenesis to inflammation and cancer.Front Oncol. 2019 Dec 12;9:1399. DOI: 10.3389/fonc.2019.01399

  101. Qian S, Golubnitschaja O, Zhan X. Chronicinfl ammation: key player and biomarker-set topredict and prevent cancer development andprogression based on individualized patient profiles. EPMA J. 2019 Nov 20;10(4):365–81.

  102. Jones D, Neal RD, Duffy SRG, Scott SE,Whitaker KL, Brain K. Comment. Impact of theCOVID-19 pandemic on the symptomatic diagnosisof cancer: the view from primary care. LancetOncol. 2020 Jun;21(6):748–50.

  103. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R,et al. Clinical characteristics of COVID- 19-infectedcancer patients: a retrospective case study inthree hospitals within Wuhan, China. Ann Oncol.2020 Jul;31(7):894–901.

  104. Ghosh S, Das S, Mondal R, Abdullah S, SultanaS, Singh S, et al. A review on the effect ofCOVID-19 in type 2 asthma and its management.Int Immunopharmacol. 2021 Feb;91:107309.DOI: 10.1016/j.intimp.2020.107309

  105. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, LianN, et al. The impact of COPD and smoking historyon the severity of COVID–19: a systemicreview and meta-analysis. J Med Virol. 2020Oct;92(10):1915–21.

  106. Liu S, Zhi Y, Ying S. COVID-19 and asthma:refl ection during the pandemic. Clin Rev AllergyImmunol. 2020 Aug;59(1):78–88.

  107. Leung JM, Yang CX, Tam A, Shaipanich T,Hackett TL, Singhera GK, et al. ACE-2 expressionin the small airway epithelia of smokersand COPD patients: implications for COVID-19.Eur Respir J. 2020 May 14;55(5):2000688.DOI: 10.1183/13993003.00688-2020

  108. Figueira Gonçalves JM, Golpe R, García-TalaveraI. Chronic obstructive pulmonary disease andSARS-CoV-2 infection. What do we know so far?Arch Bronconeumol. 2020 Jul;56 Suppl 2:5–6.English, Spanish.

  109. Kreutz R, El-Hady Algharably EA, Azizi M, DobrowolskiP, Guzik T, Januszewicz A, et al. Hypertension,the renin–angiotensin system, and therisk of lower respiratory tract infections and lunginjury: implications for COVID-19. CardiovascRes. 2020 Aug 1;116(10):1688–99.

  110. Global Strategy for Asthma Management andPrevention [Internet]. Wisconsin: Global Initiativefor Asthma; 2019 Jun [cited 2020 Dec 24].Chapter 1, Defi nition, description, and diagnosisof asthma; p. 16. Available at: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

  111. Hosoki K, Chakraborty A, Sur S. Molecular mechanismsand epidemiology of COVID- 19 froman allergist’s perspective. J Allergy Clin Immunol.2020 Aug;146(2):285–99.

  112. Carrillo T, Martínez JA, Cumplido JA. IgE yasma: El resurgir de una vieja relación. Diferentestipos de respuesta infl amatoria en el asma.Arch Bronconeumol. 2006;42 Suppl 1:13–9. DOI:10.1157/13097252. Spanish.

  113. García-Pachón E, Zamora-Molina L, Soler-Sempere MJ, Baeza-Martínez C, Grau- DelgadoJ, Canto-Reig V, et al. Asthma prevalencein patients with SARS-CoV-2 infection detectedby RT-PCR not requiring hospitalization. RespirMed. 2020 Sep;171:106084. DOI: 10.1016/j.rmed.2020.106084

  114. Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederlé C, Enache I, et al. SARS-CoV-2pneumonia in hospitalized asthmatic patients didnot induce severe exacerbation. J Allergy ClinImmunol Pract. 2020 Sep;8(8):2600–7.

  115. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A,Kudlaty E, et al. Prevalence and characterizationof asthma in hospitalized and nonhospitalizedpatients with COVID-19. J Allergy Clin Immunol.2020 Aug;146(2):307–14.e4.

  116. Skevaki C, Karsonova A, Karaulov A, XieM, Renz H. Asthma-associated risk forCOVID-19 development. J Allergy Clin Immunol.2020 Dec;146(6):1295–301.

  117. Abrams EM, ‘t Jong GW, Yang CL. Asthma andCOVID-19. CMAJ. 2020 May 19;192(20):E551.

  118. Carli G, Cecchi L, Stebbing J, Parronchi P, FarsiA. Is asthma protective against C COVID-19?Allergy. 2020 Jun 17;00:1–3. DOI: 10.1111/all.14426

  119. Holgate ST, Wenzel S, Postma DS, Weiss ST,Renz H, Sly PD. Asthma. Nat Rev Dis Primers.2015;1(1):15025. DOI:10.1038/nrdp.2015.25

  120. Mendes NF, Jara CP, Mansour E, Araújo EP, VellosoLA. Asthma and COVID-19: a systematicreview. Allergy Asthma Clin Immunol. 2021 Jan6;17(1):5.

  121. Calvielli AC, Notomi M, Wesley R. Branco ACCC,Sato MN, Alberca RW. The possible dual role ofthe ACE2 receptor in asthma and Coronavirus(SARS-CoV2) infection. Front Cell Infect Microbiol.2020 Sep 23;10:550571. DOI: 10.3389/fcimb.2020.550571

  122. Hughes-Visentin A, Mahesan Paul AB. Asthmaand COVID-19: what do we know now. ClinMed Insights Circ Respir Pulm Med. 2020 Oct23;14:1179548420966242.

  123. Öztürk AB, Çağlayan B. Angiotensin convertingenzyme-2 (ACE2) receptors, asthma and severeCOVID-19 infection risk. Eur Ann Allergy ClinImmunol. 2020 Nov;52(6):282–5.

  124. Morais-Almeida M, Pité H, Aguiar R, AnsoteguiI, Bousquet J. Asthma and the Coronavirus disease2019 pandemic: a literature review. Int ArchAllergy Immunol. 2020;181(9):680–8.




2020     |     www.medigraphic.com